Never Stop Bioteching

Biotech trials grow more decentralized, diverse, and dynamic by the day. To keep pace with change, the biotech development process needs to evolve as well. So we redesigned the journey around the patient. By pairing a highly configurable development platform with biotech teams who have the expertise and experience to anticipate and adapt throughout development, we can help you deliver on your mission to always put patients first. We call it Bioteching – and it's redefining development every step of the way.


Register now

Webinar: Oncology drug development 

Identifying regulator and payer evidence needs

The industry-wide focus on cancer has placed it at the forefront of regulatory, scientific, and clinical advances, from expedited mechanisms to biomarkers to adaptive trials. And the coronavirus pandemic has accelerated adoption of further innovations, such as decentralized clinical trials (DCTs) and real-world evidence (RWE), that regulators and payers are increasingly accepting. There will be no going back to a pre-COVID world.

To succeed, developers need to create cancer drugs that are both approvable and reimbursable. This requires a solid, integrated evidence strategy that accommodates the data to support the safety, quality and efficacy requirements of regulators, a coherent, data-driven value story for payers, and one that ultimately demonstrates how your new therapy is relevant to patients’ real lives.

No matter what you’re innovating, we can help your biotech company navigate competitive, regulatory, and reimbursement landscapes while innovating and streamlining your development plan. Learn more about Parexel Biotech solutions.

Explore our solutions

We are always available for a conversation.


Communication Preference

Communication Preference